William Blair analyst Brandon Vazquez has maintained their bullish stance on IRTC stock, giving a Buy rating on April 15.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brandon Vazquez has given his Buy rating due to a combination of factors, starting with iRhythm’s first-quarter results that exceeded consensus on both revenue and adjusted EBITDA, driven by strong procedure growth across Zio Monitor, Zio AT, and key customer segments. He highlights that Zio AT is not only winning new accounts but also deepening adoption among existing clients, reinforcing the company’s competitive position and revenue visibility.
Vazquez also points to the pending next-generation algorithm, which has been submitted for 510(k) clearance and is slated to be deployed broadly with the planned MCT launch in the first half of 2027, as a meaningful future catalyst. Despite some added regulatory noise around the MCT approval package, he emphasizes the resilience of the core business, incremental upside from innovative channels and new accounts not yet fully embedded in guidance, and favorable Medicare Advantage policy trends, all of which support upside to 2026 targets and justify maintaining an Outperform rating at roughly 4x projected 2027 sales.
In another report released on April 15, Truist Financial also maintained a Buy rating on the stock with a $170.00 price target.